
Tufts CSDD-Veeva eClinical Study CRO Report


- Assessing Data Management Practices, Performance, and Challenges
- Usage of Data Sources, Management Applications, and their Challenges



About the Tufts-Veeva 2017 eClinical Landscape Study CRO Report

- Conducted online between May July 2017
- 257 Unique Companies Responded
 - 56 unique CROs responded
- CRO Respondent Years of Experience in Clinical Data Management
 - Mean of 18.2 (median 20 years)
- 87.9% of Respondents Located in the U.S.
 - 78.6% of CROs located in U.S.

CRO Clinical Data Management Responsibility*



3 Subgroup Stratifications

Company Type*

- Sponsors (N=193)
- CROs (N=56)

Company Size (Total Clinical Trial Volume Annually)**

- Low: <5 trials, median=2 (N=56)
- Medium: 5-15 trials, median= 25 (N=56)
- High: >15 trials, median = 29 (N=56)

Primary EDC Provider ***

- Industry Leaders (Medidata & Oracle) (N=56)
- All Others (N= 201)


^{*}What is the primary role of the organization you represent?

^{**}How many clinical trials (studies) does your organization initiate each year across all phases?


^{***}What is the primary EDC application your organization uses for the majority of your studies today?

Clinical Data Management Applications Used by CROs

Percent of companies using either proprietary or commercial applications



N=56




Average Number of Clinical Trial Applications Used by CRO Size

Volume of Clinical Trials Initiated Annually	Average Number of Applications Used*	Coefficient of Variation
Low	5.0	0.28
Medium	5.0	0.50
High	6.9	0.36


*Subgroup differences are significant (p=.025)


N=56

Do the clinical studies your organization executes (directly or through a service partner) utilize any of the following applications? Please indicate all that are currently used.




Specific Clinical Data Management Applications Used by Company Type





N = 249


Types of Data CROs Manage in their Primary EDC vs Volume of Data Reported





What data does your organization manage in their primary EDC application? Select all that apply and specify the percentage of the total data attributed to each.

Data Sources Used by CROs Currently and Projected Use in 3 Years




N=56

Select the frequency with which your organization utilizes data from the following sources currently and estimate the frequency of utilization in three years




Percent of CRO Respondents Increasing Use of Any Data Source Over 3 Years



N=56

Tufts Center for the Study of Drug Development

Proportion of CRO Companies Projecting Change in Total Data Sources Used in 3 years







Magnitude of Projected Change in Data Sources Used by CROs

	Difference between reported data usage and projected usage in 3 years
EDC	0%
eCOA/ePRO	11.2%
eSource	31.1%
Informed Consent	54.3%
Smart Phone	39.0%
mHealth	46.0%
Customized Apps	26.8%
Blood Glucose Monitoring	33.7%
Personal Cardiac Monitoring	36.3%





Projected Data Sources Used in 3 Years by Company Type




*Differences are significant (p<.05)

N = 249

Select the frequency with which your organization utilizes data from the following sources currently and estimate the frequency of utilization in three years. (Data source utilization corresponds to frequencies of "always", "often", or "sometimes")

Proportion of CROs Reporting CDMS Challenges






Biggest Single Reported CDMS Challenge by Company Type

Percent Rate the Biggest Challenge	Overall (N=257)	CRO (N=56)	Sponsor (N=193)
Cycle Time Challenges (Time from Protocol – FPFV or Time from LPLV – Database Lock)	29.7%	31.5%	29.4%
Costs in Clinical R&D	29.3%	20.4%	31.0%
Number of Systems in Clinical R&D	17.5%	22.2%	16.9%
Volume of Source Data Verification	17.1%	16.7%	17.4%
Other (Protocol Related, System Related, etc.)	4.9%	3.7%	5.4%
No CDMS Challenges	1.6%	5.6%	0%

Biggest Single Reported CDMS Challenge by CRO Size

Percent Rate the Biggest Challenge	CRO (N=56)	Low Trial Volume	Medium Trial Volume	High Trial Volume
Cycle Time Challenges (Time from Protocol – FPFV or Time from LPLV – Database Lock)	31.5%	12.0%	20.6%	19.0%
Costs in Clinical R&D	20.4%	48.0%	35.3%	9.5%
Number of Systems in Clinical R&D	22.2%	8.0%	8.8%	26.2%
Volume of Source Data Verification	16.7%	12.0%	17.6%	21.4%
Other (Protocol related, system related)	3.7%	8.0%	2.9%	2.4%
No CDMS Challenges	5.6%	0.0%	5.9%	0.0%


Data Management Cycle Time for CROs



On average, how many weeks does it take for your company to build and release a study database, including all edit checks? On average, how many days do you estimate it takes from the patient visit to when the patient's data is entered into the EDC application? On average for phase II and III trials, how many days do you estimate it takes from the study's last patient out (LPO)/last patient last visites | **Tufts Center for the** Study of Drug Development (LPLV) to database lock (all data)?

TUFTS UNIVERSITY

Average Time to Build and Release a Study Database by Company Type









Average Time for Site Staff to Enter Patient Data by Company Type

Average Number of Days from Patient Visit to Data Entry in EDC






Average Time to Lock a Study Database by Company Type








Top Causes of Database Build Delays by Company Type

	Percent of Total (N=257)	CROs (N=56)	Sponsors (N=193)
Protocol Changes	45.1%	51.8%	43.5%
User Acceptance Testing (Including Review and Approvals)	16.7%	12.5%	17.6%
Database Design Functionality	15.2%	7.1%	17.6%
Study Database Move from Development into Production	8.2%	7.1%	8.8%
Standards Management	4.3%	0%	5.7%
Ethics Approval Delays/Changes	1.2%	1.8%	1.0%


Association Between Causes of Delays and Cycle Times for CROs

	CROs (N=56)	*Time from LPV to DB Lock	Coefficient of Variation
Protocol Changes	51.8%	34.3 Days	.69
User Acceptance Testing	12.5%	36.8 Days	1.08
Database Design Functionality	7.1%	59.6 Days	1.51
Study Database Move from Development into Production	7.1%	48.4 Days	.69
Standards Management	0%	44.0 Days	.34
Ethics Approval Delays/ Changes	1.8%	21.0 Days	0
Overall	100%	39.3 Days	1.11

To the best of your knowledge, what is the most common cause for delays when your organization is building clinical trial databases? On average for phase II and III trials, how many days do you estimate it takes from the study's last patient out (LPO)/last patient last visit (LPLV) to database lock (all data)?




Challenges CROs Face When Loading Data into Primary EDC




Specific Factors Preventing CROs from Loading Data into their Primary EDC


Factors Selected (Multiple)



Incidence of EDC Release After FPFV by Company Type







About

About the Tufts Center for the Study of Drug Development

The Tufts Center for the Study of Drug Development at Tufts University provides strategic information to help drug developers, regulators, and policy makers improve the quality and efficiency of pharmaceutical development, review, and utilization. Tufts CSDD conducts a wide range of in-depth analyses on pharmaceutical issues and hosts symposia, workshops, and public forums.

Tel: 617-636-2170 **Fax**: 617-636-2425

Email: csdd@tufts.edu Web: http://csdd.tufts.edu

About Veeva

Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 550 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit <u>veeva.com</u>.

Tel: (925) 452-6500

Email: EDCsurvey@veeva.com Web: https://www.veeva.com